December 11, 2025
Big Ideas, Early Data, Imminent Results: Ovid & Gain
Coverage Updates
Big Brain Idea Before the end of the year, we expect Ovid Therapeutics (Nasdaq: OVID) to release Phase 1 safety data for its intravenous potassium chloride contransporter (KCC2) direct activator, […]
November 18, 2025
Could A New Narrative Be Forming? Protara & LMs
Coverage Universe
Protara Therapeutics (Nasdaq: TARA) is expected to report interim data from its ongoing Phase 2/2b study, titled STARBORN, with TARA-002 in lymphatic malformations (LMs) in the coming weeks. Protara’s valuation […]
October 29, 2025
Ventyx: Celebrate a CRP Hit & Dismiss an Obesity Miss
Coverage Universe
Last week, Ventyx Biosciences (Nasdaq: VTYX) announced the results from a Phase 2a study with its oral CNS-penetrant NLRP3 inhibitor, VTX3232, in obese patients with cardiovascular risk factors. The data […]
October 24, 2025
More Patience Required: Delcath
Coverage Universe
This past weekend, Delcath Systems (Nasdaq: DCTH) announced clinical data from the CHOPIN study that are highly encouraging for Hepzato’s medium- to long-term growth prospects. Then, in a separate news […]
October 10, 2025
Ovid’s Data Parade & Eupraxia’s Expansion
Coverage Universe
Last week, Ovid Therapeutics (Nasdaq: OVID) announced data from its Phase 1b pharmacodynamic (PD) study with OV329, its next-generation GABA-AT inhibitor, along with a concurrent $81 million private placement. “Earlier” […]
September 25, 2025
With Biotech Risk-On, Let’s Revisit Gain & Satellos
Coverage Universe
With risk coming back on for biotech, we decided to revisit a couple of smaller names from our past that have provocative technology and near(er) term catalysts that could capture […]
September 3, 2025
Proof of Concept, FDA Alignment, and Durability: Ovid, Rezolute & Eupraxia
Coverage Universe
As September begins, one of the remaining key catalysts in our universe for Q3 is Ovid Therapeutics’ (Nasdaq: OVID) Phase 1b results for its GABA-AT inhibitor, OV329. We have discussed […]
August 22, 2025
Patience Required: Delcath & RenovoRx
Coverage Universe
Patience Required A few weeks ago, Delcath Systems (Nasdaq: DCTH) reported another strong quarter, but the stock continued to fight the headwinds caused by its May announcement that Hepzato would […]
July 17, 2025
Ovid and Xenon: Too Early to Draw Parallels?
Coverage Universe
Our Approach / Our Blindspot We don’t put buy or sell ratings on the companies we discuss. We don’t volunteer price targets. We share provocative ideas, almost always ideas that […]
July 2, 2025
Degrees of Good: Data From Nektar, Compass, and Ventyx
Coverage Universe
Over the past week, it felt like BioX (BioTwitter) was back to its old, vibrant self, and we have Nektar Therapeutics (Nasdaq: NKTR) to thank for that. The discussion started […]